MBRX
Moleculin Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.46
+1.93%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -31.5%
- EBIT
- -13.5%
- EPS
- +1.3%
- Free cash flow
- -18.8%
- Operating cash flow
- -18.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +92.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -54.7%
- EBIT
- +5.8%
- Net income
- -54.2%
- EPS
- +85.0%
- Free cash flow
- +4.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026